The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Successful use of zanubrutinib for R/R MCL in China
Yuqin Song, PhD, of Peking University Cancer Hospital & Institute, Beijing, China, discusses the promising results of a Phase II trial investigating the efficacy and safety of the BTK inhibitor zanubrutinib in relapsed/refractory mantle cell lymphoma (NCT03206970). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Song describes the best overall response rate for zanubrutinib as 84%, with adverse events generally being grade I or II.
